Reading this on a mobile device? Try our optimized mobile version here:

January 21, 2010
Sign upForwardArchiveAdvertise
News for nuclear medicine and molecular imaging professionals
The news summaries appearing in SNM SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNM prior to publication. Questions and comments may be directed to SmartBrief at

  Top Story 
  • Report predicts growth for optical molecular imaging systems
    Worldwide sales of optical molecular imaging systems could reach $400 million in 2014 and about $1 billion in the next 10 years, driven by their growing use in personalized medicine and drug research and development, a report from market research firm Strategies Unlimited said. Growth will depend on several factors, including clinical trials of imaging agents and regulatory approvals, the report said. (free registration) (1/20) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Researchers produce technetium 99m through cyclotron
    Canadian researchers used a cyclotron to produce the medical isotope technetium 99m. The researchers said the cyclotron-produced isotopes were comparable to those produced through a nuclear reactor. "The next step is to optimize production to yield technetium 99m in quantities sufficient to meet the daily demand of local hospitals," a researcher said. CNW Group (Canada)/News release (1/20) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Other News
  News from the Field 
  • Florida facility to use PEM scanner to improve breast therapy
    First Coast Oncology in Jacksonville, Fla., has acquired a positron emission mammography scanner from Naviscan to complement its AccuBoost image-guided breast irradiation procedure. The PEM scanner will allow doctors to improve detection of regions of interest before using the AccuBoost system, thus reducing exposure of healthy tissues to radiation during breast cancer therapy. PR Newswire/News release (1/20) LinkedInFacebookTwitterEmail this Story
  Featured Content 

  Health Policy 
  • FDA taps Shuren as device unit's permanent director
    FDA Commissioner Margaret Hamburg has chosen Dr. Jeffrey Shuren, who served as acting director of the agency's medical device unit, as permanent chief of the division, an agency spokeswoman said. Shuren is expected to oversee some of the unit's priorities this year, such as bolstering product reviews and ensuring a transparent decision-making process. Reuters (1/20) LinkedInFacebookTwitterEmail this Story
  Grants and Funding 
  • Researcher gets $3.7M for development of radiation test
    The Biomedical Advanced Research and Development Authority has awarded a $3.7 million grant to Dr. John Chute, a professor at Duke University in Durham, N.C., for the development of a device that would analyze blood samples to pinpoint in 30 minutes radiation damage at the genetic level. A prototype of the device is expected in 2012. The grant amount could reach $44 million if the government exercises all the option years. American City Business Journals/Raleigh/Durham, N.C. (1/20) LinkedInFacebookTwitterEmail this Story
  From SNM 
  • Register before Feb. 1 for Preclinical Imaging Workshop and save!
    Register for the In Vivo Preclinical Imaging Workshop by Feb. 1 to save $100. This small-animal imaging workshop, scheduled March 17-19, is intended for individuals new to in vivo small-animal imaging and will feature lectures as well as practical hands-on training. Limited to 25. Co-sponsored by the Center for Molecular and Genomic Imaging (UC Davis) and SNM's Molecular Imaging Center of Excellence. See for additional information and a registration form. LinkedInFacebookTwitterEmail this Story
SNM  |  Molecular Imaging Community  |  SNM Annual Meeting  |  SNM Learning Center

News  |  SNM on Facebook  |  SNM Channel on YouTube  |  SNM's Virtual March for Health

Be true! Be true! Be true! Show freely to the world, if not your worst, yet some trait whereby the worst may be inferred!"
--Nathaniel Hawthorne,
American author, from the novel "The Scarlet Letter"

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent SNM SmartBrief Issues:   Lead Editor:  Ashley McMaster
Mailing Address:
SmartBrief, Inc.®, 1100 H ST NW, Suite 1000, Washington, DC 20005
© 1999-2011 SmartBrief, Inc.® Legal Information